Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

Introduction : Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn’s disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much l...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Edyta Szymanska, Maciej Dadalski, Wieslawa Grajkowska, Sylwia Szymanska, Maciej Pronicki, Jaroslaw Kierkus
Format: Artigo
Idioma:Inglês
Publicat: Termedia Publishing House 2016-12-01
Col·lecció:Gastroenterology Review
Matèries:
adalimumab
deep remission
mucosal healing
Crohn’s disease
Accés en línia:https://www.termedia.pl/Adalimumab-for-endoscopic-and-histopathological-mucosal-healing-in-paediatric-patients-with-moderate-to-severe-Crohn-s-disease,41,28947,1,1.html
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars